No clinically relevant interaction expected. Pravastatin is not metabolised by CYP450. If treatment with an HMG-CoA reductase inhibitor is indicated, pravastatin or fluvastatin is recommended.
Kaletra Summary of Product Characteristics, AbbVie Ltd, January 2021.

Drug interaction studies reveal no clinically significant interaction between Kaletra and pravastatin. Coadministration of pravastatin (20 mg once daily for 4 days) and lopinavir/ritonavir (400/100 mg twice daily for 14 days) to 12 HIV- subjects resulted in decreases in lopinavir Cmax, AUC and Cmin of 2%, 5% and 12% respectively. Pravastatin Cmax increased by 26% and AUC by 33%.
Kaletra Prescribing Information, AbbVie Ltd, October 2020.

Coadministration of pravastatin (20 mg once daily for 4 days) and lopinavir (400/100 mg twice daily for 14 days) was studied in 12 healthy volunteers and resulted in no clinically significant interaction. Lopinavir ratios (with/without pravastatin) for Cmax, AUC and Cmin were 0.98, 0.95 and 0.88, respectively (1 = no effect). Ratios (with/without lopinavir) for pravastatin Cmax and AUC were 1.26 and 1.33, respectively.
Concomitant administration of ABT-378/ritonavir. Results in a clinically important pharmacokinetic interaction with atorvastatin but not pravastatin. Carr TA, Andre AK, Bertz RJ, et al. 40th ICAAC, Toronto, September 2000, presentation 1644.